Zalicus' Z160 Receives Orphan Drug Designation for the Management of Postherpetic Neuralgia

Zalicus Inc. , a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel modulator in development for chronic neuropathic pain has received Orphan Drug designation from the U.S. Food and Drug ... (more)

http://it.tmcnet.com/news/2013/09/27/7442641.htm